DMAC DiaMedica Therapeutics Inc.

4.28
-0.28  -6%
Previous Close 4.56
Open 4.58
Price To Book 3.69
Market Cap 51,389,421
Shares 11,956,874
Volume 53,174
Short Ratio
Av. Daily Volume 129,472

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2019 or 1Q 2020.
DM199 - Remedy
Acute ischaemic stroke
Phase 2 trial to be initiated 2019/2020.
DM199
Vascular dementia
Phase 1b data June 19, 2019 noted favorable safety profile. Phase 2 initiation expected 2H 2019 with interim analysis 4Q 2019 - 1Q 2020
DM199
Chronic Kidney Disease

Latest News

  1. The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
  2. The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge
  3. DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
  4. DiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease
  5. DiaMedica Therapeutics, Inc. to Host Earnings Call
  6. DiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update
  7. DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019
  8. DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
  9. DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
  10. DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
  11. DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
  12. DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
  13. DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
  14. OTC Markets Group Announces Quarterly Index Performance and Rebalancing
  15. The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
  16. DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
  17. UPDATE - DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
  18. IPO Outlook For The Week: Proteins, Fashion And Finance